Liquid Biopsy

Molecular Information Directly from a Blood Sample

Liquid biopsy enables precise, noninvasive diagnostics based on circulating tumor DNA (ctDNA). It provides essential molecular insights into tumor biology — quickly, reliably, and with minimal burden to the patient. Whether for initial diagnosis, therapy selection, or monitoring, CEBIO offers analytically validated liquid biopsy procedures, robust data interpretation, and clinically meaningful results — grounded in scientific rigor.

Molecular analyses are conducted in close collaboration with the Munich Biomarker Research Center, TUM Hospital German Heart Center. Their diagnostic expertise in circulating biomarkers, combined with extensive research experience in liquid biopsy, ensures the highest quality and clinical relevance of our results.

Liquid Biopsy – Molecular Profiling of Tumors via ctDNA Analysis
CEBIO applies high-sensitivity methods such as next-generation sequencing (NGS) and digital PCR (dPCR) to analyze circulating tumor DNA (ctDNA) from plasma samples. This enables molecular characterization of solid tumors, detection of resistance mutations, and monitoring of minimal residual disease. Our assays are supported by standardized workflows and validated reference materials to ensure analytical robustness and clinical utility.

Learn more

Liquid Biopsy – Clear Answers from a Simple Blood Draw
Liquid biopsy enables doctors to analyze tumor-specific DNA fragments circulating in your blood – without surgery or tissue removal. This modern method supports therapy selection, treatment monitoring, and the early detection of recurrence. The test is minimally invasive, quick, and can be repeated as needed throughout your care journey.

Learn more
Drag